Production (Stage)
Atai Life Sciences N.V.
ATAI
$2.30
$0.0853.85%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.86M | 308.00K | 331.00K | 378.00K | 277.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.86M | 308.00K | 331.00K | 378.00K | 277.00K |
| Cost of Revenue | 10.84M | 11.23M | 11.23M | 11.23M | 11.23M |
| Gross Profit | -8.98M | -10.92M | -10.90M | -10.85M | -10.95M |
| SG&A Expenses | 45.09M | 46.06M | 54.44M | 57.81M | 60.97M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 98.81M | 100.17M | 104.41M | 108.69M | 114.72M |
| Operating Income | -96.95M | -99.86M | -104.08M | -108.31M | -114.44M |
| Income Before Tax | -149.89M | -151.14M | -132.59M | -62.49M | -38.72M |
| Income Tax Expenses | -749.00K | -1.09M | -2.39M | -1.97M | -1.80M |
| Earnings from Continuing Operations | -149.14 | -150.05 | -130.20 | -60.52 | -36.92 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 149.00K | 780.00K | 1.60M | 2.45M | 3.12M |
| Net Income | -148.99M | -149.27M | -128.60M | -58.07M | -33.80M |
| EBIT | -96.95M | -99.86M | -104.08M | -108.31M | -114.44M |
| EBITDA | -96.34M | -99.39M | -103.73M | -107.97M | -114.11M |
| EPS Basic | -0.91 | -0.93 | -0.80 | -0.36 | -0.21 |
| Normalized Basic EPS | -0.57 | -0.59 | -0.60 | -0.59 | -0.50 |
| EPS Diluted | -0.91 | -0.93 | -0.81 | -0.39 | -0.25 |
| Normalized Diluted EPS | -0.57 | -0.59 | -0.60 | -0.58 | -0.49 |
| Average Basic Shares Outstanding | 657.99M | 640.61M | 638.74M | 633.91M | 629.32M |
| Average Diluted Shares Outstanding | 657.99M | 640.61M | 638.74M | 655.69M | 651.09M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |